Literature DB >> 1995267

Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini.

K Miyasaka1, A Funakoshi, M Matsumoto, R Nakamura, S Sakamoto, H Sakai, K Kitani.   

Abstract

A bioassay using dispersed pancreatic acini was used to measure fasting plasma cholecystokinin (CCK) concentrations in 105 patients with various kinds of gastrointestinal diseases, 17 patients with diabetes mellitus, and 6 healthy volunteers. High plasma CCK bioactivities were observed in patients with obstructive jaundice, choledocolithiasis, and primary biliary cirrhosis. Twenty-three samples with high CCK bioactivities were assayed by the same bioassay after the addition of a specific CCK antagonist and by a CCK radioimmunoassay in order to determine whether the high CCK-like bioactivity was due to circulating CCK or other factors. High CCK bioactivities were partially inhibited by the specific CCK antagonist, CR-1409, but the activities were not totally abolished. The residual bioactivities (not inhibited by CR-1409) correlated with plasma bile acid concentrations. The inhibitable CCK bioactivities correlated with plasma CCK levels obtained by radioimmunoassay. Although the bioassay using dispersed pancreatic acini has several advantages for measuring plasma CCK, this method overestimates CCK bioactivities in patients with high plasma bile acid concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995267     DOI: 10.1007/bf01318202

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  [Basal plasma cholecystokinin levels in digestive diseases--comparison between CCK-8 like bioactivity by bioassay and CCK immunoreactivity by radioimmunoassay].

Authors:  R Nakamura; K Miyasaka; A Funakoshi; K Kitani; Y Kuyama; N Goseki; K Kino; M Tsuru; T Fukazawa
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1989-11

2.  A new and rapid method for the clinical determination of alpha-amylase activities in human serum and urine. Optimal conditions.

Authors:  M Ceska; K Birath; B Brown
Journal:  Clin Chim Acta       Date:  1969-12       Impact factor: 3.786

3.  Immunochemical evidence of cholecystokinin-like peptides in brain.

Authors:  G J Dockray
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

4.  Partial structure of a large canine cholecystokinin (CCK58): amino acid sequence.

Authors:  V E Eysselein; J R Reeve; J E Shively; D Hawke; J H Walsh
Journal:  Peptides       Date:  1982 Jul-Aug       Impact factor: 3.750

5.  Immunoreactive component resembling cholecystokinin octapeptide in intestine.

Authors:  G J Dockray
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

6.  Bile inhibits release of cholecystokinin and neurotensin.

Authors:  G Gomez; F Lluis; Y S Guo; G H Greeley; C M Townsend; J C Thompson
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

7.  Cholecystokinin mediates feedback regulation of pancreatic enzyme secretion in rats.

Authors:  D S Louie; D May; P Miller; C Owyang
Journal:  Am J Physiol       Date:  1986-02

8.  Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction.

Authors:  G J Gores; N F LaRusso; L J Miller
Journal:  Am J Physiol       Date:  1986-03

9.  Cholecystokinin and its COOH-terminal octapeptide in the pig brain.

Authors:  J E Muller; E Straus; R S Yalow
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

10.  The inhibitory effect of CR-1409 on amylase secretion and intracellular Ca2+ mobilization in rat pancreatic acini in vitro.

Authors:  H Shinozaki; A Funakoshi; H Wakasugi; M Abe
Journal:  Jpn J Physiol       Date:  1989
View more
  1 in total

1.  Role of endogenous bile on basal and postprandial CCK release in humans.

Authors:  M Koide; Y Okabayashi; M Otsuki
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.